Thrombolex
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $50M
Investors
- 1
About Thrombolex
Thrombolex Inc. is a US-based medical technology company focused on developing innovative endovascular solutions for treating thromboembolic conditions., founded in 2016 and headquartered in the United States, specializes in developing advanced medical devices for thromboembolic treatment.Thrombolex, Inc. specializes in the development of innovative endovascular catheters aimed at treating arterial and venous thromboembolic (A+VTE) conditions. The core product offerings include the BASHIR™ Family of Endovascular Catheters, which utilize a unique hybrid mechanism that combines mechanical and pharmacological therapies to restore blood flow safely and effectively. These devices, notably the BASHIR™ Plus and BASHIR™ S-B catheters, are designed to enable the targeted delivery of thrombolytics through an expandable infusion basket, facilitating both immediate clot resolution and controlled fluid infusion. The primary customer base comprises hospitals and healthcare providers specializing in interventional cardiology and vascular surgery, primarily across the United States and select markets in Europe and Asia.Thrombolex generates revenue through direct sales of its endovascular catheter products to healthcare facilities, which engage in standard procurement practices for medical supplies. The transaction structure is primarily B2B, where hospitals and clinics purchase these devices based on their clinical needs and patient volume. The pricing strategy for the BASHIR™ family of products is aligned with industry standards for advanced medical devices, reflecting the value of their unique features and clinical efficacy. Revenue is bolstered by partnerships with medical device distributors, which facilitate broader access to these products across various healthcare markets.In March 2026, Thrombolex Inc.S. commercial infrastructure and advance clinical evidence generation across its endovascular catheter platform. The company plans to launch new product developments that enhance treatment for thromboembolic conditions, though specific product details and release dates have not been disclosed. Additionally, Thrombolex is targeting expansion into select international markets in Europe and Asia by the end of 2026.
Who invested in Thrombolex
1 investor across 1 round
See all investors in Thrombolex
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 16, 2026
Amount
$50M
Investors
Questions about Thrombolex
Who invested in Thrombolex?
Thrombolex has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Thrombolex raised?
Thrombolex has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Thrombolex last raise money?
Thrombolex's most recent round on record is a Series A, in Mar 2026.
What does Thrombolex do?
Thrombolex is a medical devices & equipment company.
Where is Thrombolex headquartered?
Thrombolex is headquartered in US.
Which VCs invest in companies like Thrombolex?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Thrombolex's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Thrombolex? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.